368 related articles for article (PubMed ID: 35053457)
1. Potential Role of CXCL13/CXCR5 Signaling in Immune Checkpoint Inhibitor Treatment in Cancer.
Hsieh CH; Jian CZ; Lin LI; Low GS; Ou PY; Hsu C; Ou DL
Cancers (Basel); 2022 Jan; 14(2):. PubMed ID: 35053457
[TBL] [Abstract][Full Text] [Related]
2. Adaptive antitumor immune response stimulated by bio-nanoparticle based vaccine and checkpoint blockade.
Bai X; Zhou Y; Yokota Y; Matsumoto Y; Zhai B; Maarouf N; Hayashi H; Carlson R; Zhang S; Sousa A; Sun B; Ghanbari H; Dong X; Wands JR
J Exp Clin Cancer Res; 2022 Apr; 41(1):132. PubMed ID: 35392977
[TBL] [Abstract][Full Text] [Related]
3. CXCL13 shapes immunoactive tumor microenvironment and enhances the efficacy of PD-1 checkpoint blockade in high-grade serous ovarian cancer.
Yang M; Lu J; Zhang G; Wang Y; He M; Xu Q; Xu C; Liu H
J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33452206
[TBL] [Abstract][Full Text] [Related]
4. PD-1
Li JP; Wu CY; Chen MY; Liu SX; Yan SM; Kang YF; Sun C; Grandis JR; Zeng MS; Zhong Q
J Immunother Cancer; 2021 Jul; 9(7):. PubMed ID: 34253636
[TBL] [Abstract][Full Text] [Related]
5. Antigen presentation by clonally diverse CXCR5+ B cells to CD4 and CD8 T cells is associated with durable response to immune checkpoint inhibitors.
Ding L; Sun L; Bu MT; Zhang Y; Scott LN; Prins RM; Su MA; Lechner MG; Hugo W
Front Immunol; 2023; 14():1176994. PubMed ID: 37435085
[TBL] [Abstract][Full Text] [Related]
6. CXCL13 in Cancer and Other Diseases: Biological Functions, Clinical Significance, and Therapeutic Opportunities.
Gao SH; Liu SZ; Wang GZ; Zhou GB
Life (Basel); 2021 Nov; 11(12):. PubMed ID: 34947813
[TBL] [Abstract][Full Text] [Related]
7. Tertiary lymphoid structures marker CXCL13 is associated with better survival for patients with advanced-stage bladder cancer treated with immunotherapy.
Groeneveld CS; Fontugne J; Cabel L; Bernard-Pierrot I; Radvanyi F; Allory Y; de Reyniès A
Eur J Cancer; 2021 May; 148():181-189. PubMed ID: 33743486
[TBL] [Abstract][Full Text] [Related]
8. Revisiting the Role of the CXCL13/CXCR5-Associated Immune Axis in Melanoma: Potential Implications for Anti-PD-1-Related Biomarker Research.
Hoellwerth M; Koelblinger P; Lang R; Harrer A
Life (Basel); 2023 Feb; 13(2):. PubMed ID: 36836910
[TBL] [Abstract][Full Text] [Related]
9. CXCL13 and Its Receptor CXCR5 in Cancer: Inflammation, Immune Response, and Beyond.
Kazanietz MG; Durando M; Cooke M
Front Endocrinol (Lausanne); 2019; 10():471. PubMed ID: 31354634
[TBL] [Abstract][Full Text] [Related]
10. CXCL13 Positive Cells Localization Predict Response to Anti-PD-1/PD-L1 in Pulmonary Non-Small Cell Carcinoma.
Vahidian F; Lamaze FC; Bouffard C; Coulombe F; Gagné A; Blais F; Tonneau M; Orain M; Routy B; Manem VSK; Joubert P
Cancers (Basel); 2024 Feb; 16(4):. PubMed ID: 38398098
[No Abstract] [Full Text] [Related]
11. CXCL13/CXCR5 signaling axis in cancer.
Hussain M; Adah D; Tariq M; Lu Y; Zhang J; Liu J
Life Sci; 2019 Jun; 227():175-186. PubMed ID: 31026453
[TBL] [Abstract][Full Text] [Related]
12. Role of the CXCL13/CXCR5 Axis in Autoimmune Diseases.
Pan Z; Zhu T; Liu Y; Zhang N
Front Immunol; 2022; 13():850998. PubMed ID: 35309354
[TBL] [Abstract][Full Text] [Related]
13. The CXCL13/CXCR5 Immune Axis in Health and Disease-Implications for Intrathecal B Cell Activities in Neuroinflammation.
Harrer C; Otto F; Radlberger RF; Moser T; Pilz G; Wipfler P; Harrer A
Cells; 2022 Aug; 11(17):. PubMed ID: 36078057
[TBL] [Abstract][Full Text] [Related]
14. Transcriptional upregulation of CXCL13 is correlated with a favorable response to immune checkpoint inhibitors in lung adenocarcinoma.
Park S; Cha H; Kim HS; Lee B; Kim S; Kim TM; Jung HA; Sun JM; Ahn JS; Ahn MJ; Park K; Park WY; Lee SH
Cancer Med; 2023 Mar; 12(6):7639-7650. PubMed ID: 36453453
[TBL] [Abstract][Full Text] [Related]
15. Overexpression of the CXCR5 chemokine receptor, and its ligand, CXCL13 in B-cell chronic lymphocytic leukemia.
Bürkle A; Niedermeier M; Schmitt-Gräff A; Wierda WG; Keating MJ; Burger JA
Blood; 2007 Nov; 110(9):3316-25. PubMed ID: 17652619
[TBL] [Abstract][Full Text] [Related]
16. The CXCL13/CXCR5-chemokine axis in neuroinflammation: evidence of CXCR5+CD4 T cell recruitment to CSF.
Harrer C; Otto F; Pilz G; Haschke-Becher E; Trinka E; Hitzl W; Wipfler P; Harrer A
Fluids Barriers CNS; 2021 Aug; 18(1):40. PubMed ID: 34446066
[TBL] [Abstract][Full Text] [Related]
17. Identification of CXCL13/CXCR5 axis's crucial and complex effect in human lung adenocarcinoma.
Tian C; Li C; Zeng Y; Liang J; Yang Q; Gu F; Hu Y; Liu L
Int Immunopharmacol; 2021 May; 94():107416. PubMed ID: 33676174
[TBL] [Abstract][Full Text] [Related]
18. CXC chemokine ligand 13 and CC chemokine ligand 19 cooperatively render resistance to apoptosis in B cell lineage acute and chronic lymphocytic leukemia CD23+CD5+ B cells.
Chunsong H; Yuling H; Li W; Jie X; Gang Z; Qiuping Z; Qingping G; Kejian Z; Li Q; Chang AE; Youxin J; Jinquan T
J Immunol; 2006 Nov; 177(10):6713-22. PubMed ID: 17082584
[TBL] [Abstract][Full Text] [Related]
19. CXCL13 Signaling in the Tumor Microenvironment.
Hussain M; Liu J; Wang GZ; Zhou GB
Adv Exp Med Biol; 2021; 1302():71-90. PubMed ID: 34286442
[TBL] [Abstract][Full Text] [Related]
20. CXCL13-mediated recruitment of intrahepatic CXCR5
Li Y; Tang L; Guo L; Chen C; Gu S; Zhou Y; Ye G; Li X; Wang W; Liao X; Wang Y; Peng X; Liu G; Zhang X; Sun J; Peng J; Hou J
J Hepatol; 2020 Mar; 72(3):420-430. PubMed ID: 31610223
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
